Canada markets closed

Gemina Laboratories Ltd. (GLABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.55000.0000 (0.00%)
At close: 03:18PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5500
BidN/A x N/A
AskN/A x N/A
Day's Range0.5500 - 0.5500
52 Week Range0.3700 - 0.5500
Avg. Volume0
Market Cap20.365M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A

    Gemina Labs Presents at the H.C. Wainwright Global Investment Conference

    Gemina Laboratories Ltd.(CSE:GLAB) (FRA:8I7) (US:OTC GLABF) (the "Company" or "Gemina") is pleased to announce its participation both virtually and in person at the H.C. Wainwright 24th Annual Global Investment Conference. Gemina's presentation hosted by CEO Brian Firth, will be available for viewing on Monday September 12, 2022, beginning at 7:00 a.m. EST. Mr. Firth will also be attending the live event and available for one on one meetings.


    Gemina Labs Appoints Diagnostic Executive Brian Firth as Chief Executive Officer

    Gemina Laboratories Ltd.(CSE:GLAB) (FRA:8I7) (US:OTC:GLABF) (the "Company" or "Gemina") is excited to announce the appointment of Brian Firth, an accomplished diagnostic industry executive, as the Company's new Chief Executive Officer. Gemina is also pleased to announce the appointment of founding CEO John Davies, as Chairman of the Board of Directors.


    Gemina Labs Announces Closing Of Concurrent Private Placement

    VANCOUVER, BC / ACCESSWIRE / July 11, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the closing of its previously announced non-brokered private placement (the "Private Placement"), raising gross proceeds of $921,720 through the issuance of 1,536,200 units (the "Units") at a price of $0.